Xbrane Biopharma Ab Stock Annual Yield
| XBRANE Stock | SEK 0.17 0.01 5.56% |
Xbrane Biopharma AB fundamentals help investors to digest information that contributes to Xbrane Biopharma's financial success or failures. It also enables traders to predict the movement of Xbrane Stock. The fundamental analysis module provides a way to measure Xbrane Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xbrane Biopharma stock.
Xbrane |
Xbrane Biopharma AB Company Annual Yield Analysis
Xbrane Biopharma's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Xbrane Biopharma AB has an Annual Yield of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Drug Manufacturers - Specialty & Generic (which currently averages 0.0) industry. This indicator is about the same for all Sweden stocks average (which is currently at 0.0).
Did you try this?
Run Odds Of Bankruptcy Now
Odds Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years |
| All Next | Launch Module |
Xbrane Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.13 | |||
| Operating Margin | (4.61) % | |||
| Current Valuation | 2.32 B | |||
| Shares Outstanding | 27.51 M | |||
| Shares Owned By Insiders | 35.23 % | |||
| Shares Owned By Institutions | 22.09 % | |||
| Price To Earning | (10.92) X | |||
| Price To Book | 7.49 X | |||
| Price To Sales | 75.09 X | |||
| Revenue | 11.53 M | |||
| Gross Profit | (18.27 M) | |||
| EBITDA | (172.74 M) | |||
| Net Income | (188.38 M) | |||
| Cash And Equivalents | 44.32 M | |||
| Cash Per Share | 5.34 X | |||
| Total Debt | 36.48 M | |||
| Debt To Equity | 48.90 % | |||
| Current Ratio | 1.45 X | |||
| Book Value Per Share | 12.99 X | |||
| Cash Flow From Operations | (219.61 M) | |||
| Earnings Per Share | (7.13) X | |||
| Target Price | 136.5 | |||
| Number Of Employees | 74 | |||
| Beta | 1.37 | |||
| Market Capitalization | 2.74 B | |||
| Total Asset | 688.43 M | |||
| Retained Earnings | (29 M) | |||
| Working Capital | 64 M | |||
| Current Asset | 77 M | |||
| Current Liabilities | 13 M | |||
| Z Score | 45.0 | |||
| Net Asset | 688.43 M |
About Xbrane Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xbrane Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xbrane Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xbrane Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Xbrane Stock
Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.